• In recent days, Merck and Moderna reported five-year follow-up data showing that their personalized mRNA melanoma therapy, when combined with Keytruda, substantially lowered the risk of recurrence or death in high-risk patients.
• This clinical milestone, alongside new collaborations in AI-driven drug discovery, diagnostics, and vaccine development, reinforces Merck’s push to broaden its oncology and infectious disease platforms beyond Keytruda.
• We’ll now examine how the mRNA melanoma data and broader R&D partnerships could influence Merck’s longer-term investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.

What Is Merck's Investment Narrative?

To own Merck today, you have to believe its push to build a broader oncology and infectious disease engine can gradually rebalance the business away from Keytruda while still justifying a premium for its high margins, strong free cash flow and long dividend record. The new five‑year melanoma data with Moderna’s mRNA therapy, plus fresh alliances in AI drug discovery, diagnostics and vaccines, slot directly into that story by sharpening near‑term catalysts around the oncology pipeline rather than changing it outright. Recent collaborations with Guardant, Illumina’s Billion Cell Atlas and CEPI on an improved Ebola vaccine all point to Merck trying to translate its cash flows into a deeper, tech‑enabled pipeline, even as analysts still flag the late‑decade Keytruda patent cliff, high debt levels and some policy risk around vaccines as the main overhangs.

However, one risk around Keytruda’s future cash flows is easy to underestimate. Despite retreating, Merck's shares might still be trading 48% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

The Simply Wall St Community’s 24 fair value estimates for Merck span roughly US$83 to just over US$209 per share, showing how far apart individual investors can be. Set that against Merck’s renewed oncology momentum and the looming Keytruda patent overhang, and you can see why it pays to weigh several competing views on where the business goes next.

Explore 24 other fair value estimates on Merck - why the stock might be worth as much as 93% more than the current price!

Build Your Own Merck Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Merck research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.